Journal of opioid management最新文献

{"title":"Complications of opioid use disorder in hospitalized patients with serious infections: A retrospective analysis of clinical course and outcomes.","authors":"Rachel Gnanaprakasam, Emily Zhang, Adam Ferin, Marc Y El Khoury","doi":"10.5055/jom.0962","DOIUrl":"https://doi.org/10.5055/jom.0962","url":null,"abstract":"<p><strong>Background: </strong>Opioid use disorder (OUD) poses significant public health threats at epidemic levels in the United States. Injection drug use (IDU) is particularly associated with serious infections, leading to increased risk for complications and poor outcomes. This study aims to characterize the complications and outcomes among patients with OUD who are hospitalized for the management of various infections. Additionally, a comparison of outcomes was performed between the group of patients with OUD who do not inject drugs (non-PWID) and the group of persons who inject drugs (PWID).</p><p><strong>Methods: </strong>We performed a retrospective chart review using data obtained via the hospital electronic medical record. The study population included adults with inpatient hospitalizations at Westchester Medical Center and Mid-Hudson Regional Hospital, with International Classification of Diseases, Tenth Revision codes for opioid dependence, OUD, and infections from December 2020 to December 2021. The sample size included 51 patients. Statistical analysis was performed to assess outcomes such as length of stay (LOS), complications during hospitalization, and duration of antibiotic use.</p><p><strong>Results: </strong>Among the 51 patients who met the inclusion criteria, 26 (51.0 percent) had a history of IDU, 20 (39.2 percent) had opioid dependence but did not inject drugs, and five (9.8 percent) were patients with unspecified OUD diagnosis. Of the 26 patients in the PWID group, 16 (61.5 percent) experienced complications during their hospitalization compared to three out of 20 (15 percent) in the non-PWID group (p = 0.002). Complications included either metastatic spread of infection or a requirement for surgical intervention. The mean age in the PWID group was 39.9 years compared to 56.7 years in the non-PWID group (p < 0.001). Mean LOS for PWID was 10.35 days, compared to 9.25 days in the other group (p = 0.708). The mean duration of antimicrobial therapy was longer in the PWID group, 21.32 days compared to 13.68 days in the non-PWID group (p = 0.010).</p><p><strong>Conclusions: </strong>PWID were younger, more likely to experience complications during their hospitalization, and required a longer duration of antibiotics compared to those who have OUD but do not inject drugs. Infection-related hospitalization of patients with OUD represents an opportunity to provide addiction treatment, counseling, and harm reduction strategies.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"22 3","pages":"251-257"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From stigma to science: The association of terminology shifts with fentanyl-related research focus and collaboration.","authors":"Nicholas Vo, Bharath Chakravarthy, Soheil Saadat","doi":"10.5055/jom.0988","DOIUrl":"10.5055/jom.0988","url":null,"abstract":"<p><strong>Objective: </strong>Terminology used in scientific literature is associated with resource allocation, research prioritization, and public perception. The aim of this study is to describe how research on fentanyl is associated with a change in terminology used to refer to its use.</p><p><strong>Design: </strong>The study utilized bibliometric analysis of 11,982 publications from 2000 to 2023 from Web of Science using the topic search terms \"Fentanyl\" and \"Humans.\" These articles were then analyzed via VOSViewer and Microsoft Excel.® Results: Publications adopting nonstigmatizing terminology were more frequently connected to research on substance use treatment, rehabilitation, and medication-assisted treatments (methadone, naltrexone, buprenorphine). The adaptation demonstrated greater connections to these medications, methadone, naltrexone, and buprenorphine, and reflects an emerging focus on fentanyl-specialized addiction medicine.</p><p><strong>Conclusions: </strong>Older publications frequently utilized stigmatizing terminology and lacked a coherent research direction. Conversely, recent adoption of nonstigmatizing language coincides with increased research output focusing on treatment, emergency overdose management, epidemiology, and public health. Notably, the adoption of nonstigmatized terms coincides with increased publications and a new focus on fentanyl-related research.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"22 3","pages":"289-297"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global narcotics regulations: An overview of international drug control conventions and the need for responsible legal regulation.","authors":"Vishesh Sahu, Simran Kaur, Simran Yadav, Navneet Sharma, Vikesh Kumar Shukla","doi":"10.5055/jom.0925","DOIUrl":"10.5055/jom.0925","url":null,"abstract":"<p><p>This article aims to perform a comparative systematic review of regulations of narcotic substances between the years 2017 and 2024. The regulation of narcotics and psychotropic substances encompasses a complex web of international treaties, national laws, and regulatory frameworks aimed at controlling their production, distribution, prescription, and use. The current review explores the import and prescription regulations of narcotics in various countries. Key regulatory agencies include the Drug Enforcement Agency and Food and Drug Administration in the United States (US), Office of Drug Control (ODC) in Australia, Narcotics Control Department in Japan, and United Nations (UN) Office of Drugs and Crime and Commission on Narcotic Drugs under the UN. In the US, the Controlled Substances Act categorizes substances based on abuse potential and medical utility. Australia's regulatory framework is overseen by the Therapeutic Goods Administration and ODC. Japan regulates through the Stimulants Control Act and the Narcotics and Psychotropic Substances Control Act, 1953. The United Kingdom enforces the Misuse of Drugs Act 1971, while India employs the Narcotic Drugs and Psychotropic Substances Act, 1985. It was observed that there were certain lacunae in the regulation, such as the lack of Prescription Monitoring Programs in a few countries, nonavailability of global database containing information about drug trafficking operations, such as routes, techniques, etc., and the nonuniformity within the regulations. Overall, the regulation of narcotics and psychotropic substances involves a delicate balance between control and accessibility, with ongoing debates and reforms shaping the global drug control regime. The current article provides a useful resource for policymakers and stakeholders in the field of narcotic substances.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"22 3","pages":"309-327"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the impact of the method of anesthesia on intraoperative nociceptive response during spine surgeries: Prospective randomized control trial.","authors":"Maksym Barsa","doi":"10.5055/jom.0943","DOIUrl":"10.5055/jom.0943","url":null,"abstract":"<p><strong>Background: </strong>Surgical intervention triggers nociception, whereas the main aim of anesthesia is to suppress nociceptive signal processing. The impact of different methods of anesthesia on the nociceptive response and their correlation with post-operative outcomes remains unclear. Regional anesthesia affects transduction, transmission, and modulation by interrupting the conduction of pain impulses by local anesthetics. Moreover, nerve blocks influence pain perception by reducing opioid consumption (OC), which helps prevent the development of pain sensitization and opioid tolerance. Owing to this mechanism, an essential balance between nociception and antinociception is sustained, and violation of this balance can lead to post-operative complications.</p><p><strong>Aim: </strong>To compare the impact of general anesthesia (GA) with erector spinae plane block (ESPB) versus GA without ESPB on intraoperative nociceptive response index (NRI), OC, post-operative pain intensity (PPI), and hyperalgesia in patients undergoing spine surgery.</p><p><strong>Methods: </strong>This prospective, randomized controlled study was conducted in a clinical hospital with an affiliate university department, from December 2021 to November 2022. A total of 151 patients who underwent spine surgery via the posterior approach were randomly assigned to either the GA control group (CG) or the GA with ESPB study group (SG).</p><p><strong>Outcomes: </strong>NRI, OC, PPI, and hyperalgesia. This study was registered at ClinicalTrials.gov (identification number: NCT04697498 at December 12, 2020, https://clinicaltrials.gov/study/NCT04697498).</p><p><strong>Results: </strong>Average NRI during surgery differed between groups: 0.66 ± 0.28 in the SG and 0.86 ± 0.19 in the CG. Amount of fentanyl and morphine was lower in the SG (1.84 ± 0.75 µg/kg; 5.62 ± 5.00 mg) compared with the CG (3.64 ± 1.2 µg/kg; 28.97 ± 9.75 mg), respectively. PPI at rest and during movement was higher in the CG after surgery than in the SG at all stages of observation. Mechanical pain threshold (MPT) did not differ before surgery: 21.05 ± 6.64 in the SG; 21.55 ± 6.06 in the CG. After surgery, the MPT was lower in the CG, 5.60 ± 1.93, than in the SG, 23.26 ± 6.8. NRI had the strongest negative correlation with hyperalgesia in comparison with other data.</p><p><strong>Conclusions: </strong>ESPB, as a component of GA, decreases NRI, OC, and PPI. As a result, it does not trigger hyperalgesia after spine surgery.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"22 3","pages":"259-268"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of oral tizanidine and baclofen for post-operative pain management after femoral fracture surgery.","authors":"Goli Aezzi, Seyed Abdollah Emadi, Salman Ghaffari, Ali Safarpour, Farshad Hassanzadeh Kiabi","doi":"10.5055/jom.0994","DOIUrl":"10.5055/jom.0994","url":null,"abstract":"<p><strong>Objectives: </strong>Effective post-operative pain management enhances patients' quality of life and reduces post-operative immobility. To compare the analgesic efficacy of preoperative tizanidine versus baclofen in patients undergoing femoral fracture surgery.</p><p><strong>Design: </strong>In this double-blind clinical trial, 50 patients were randomized to receive either 4 mg tizanidine (Group A) or 25 mg baclofen (Group B) orally before surgery. Post-operative pain was managed with an analgesic pump containing morphine and paracetamol. Pain intensity, nausea, vomiting, pruritus, and analgesic use were assessed upon entering the recovery ward and at 2, 4, 6, 12, 24, and 48 hours post-surgery.</p><p><strong>Results: </strong>Pain intensity, measured by the Visual Analog Scale (VAS), decreased significantly over time in both the tizanidine and baclofen groups (p < 0.001). Although a group-by-time interaction was initially observed (p = 0.042), further analysis revealed this to be a trend rather than a robust difference in the primary outcome. Specifically, at 6, 24, and 48 hours post-surgery, VAS scores were 3.08 ± 1.63, 2.88 ± 1.01, and 2.08 ± 1.04 in the tizanidine group, compared to 3.92 ± 1.29, 3.56 ± 1.16, and 2.84 ± 1.57 in the baclofen group. While uncorrected p-values for these intervals were 0.049, 0.032, and 0.049, respectively, none reached statistical significance after applying the Bonferroni correction for multiple comparisons (p > 0.0167). Additionally, there were no significant differences between groups regarding total morphine consumption or the incidence of adverse effects.</p><p><strong>Conclusions: </strong>Preoperative administration of 4 mg tizanidine and 25 mg baclofen showed comparable efficacy in post-operative pain management. As this study lacked a placebo control, it cannot confirm the absolute analgesic efficacy of either drug over no treatment. Although tizanidine demonstrated a trend toward lower pain scores at certain intervals, these differences were not statistically significant after adjustment for multiple comparisons. Both drugs exhibited similar safety profiles and supplemental analgesic requirements.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"22 3","pages":"279-287"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of post-operative pain by metoclopramide in patients undergoing cesarean section: A double-blinded randomized clinical trial.","authors":"Farshad Hassanzadeh Kiabi, Afshin Gholipour Baradari, Alieh Zamani Kiasari, Goli Aezzi, Sara Malekshah","doi":"10.5055/jom.0955","DOIUrl":"10.5055/jom.0955","url":null,"abstract":"<p><strong>Objective: </strong>Poor post-operative pain management after cesarean section (C-section) can have adverse effects on the mother and baby and is associated with increased opioid intake. This study aims to evaluate the effects of the dopamine antagonist, metoclopramide, on the management of post-operative pain among women undergoing elective C-sections.</p><p><strong>Method: </strong>This double-blinded randomized study included women who underwent C-sections at our center. The patients were divided into an intervention group and a control group. The intervention group received 20 mg metoclopramide, whereas the control group was given 2 cc of distilled water as a placebo, intravenously, post-operatively, before the closing of the surgical site. At 2, 4, 6, 8, 12, and 24 post-operative hours, data regarding pain (measured via a visual analog scale), nausea and vomiting, and resumption of physical activity were obtained along with the demographic information of the patients.</p><p><strong>Results: </strong>Fifty patients were included in both groups. The mean age, body mass index, number of previous deliveries, education, smoking status, and number of previous C-sections were not significantly different between the two groups. Metoclopramide reduced early post-cesarean pain (Visual Analog Scale [VAS]: 7.38 vs 8.48 at 2 hours, *p < 0.001) and morphine use (18.7 mg vs 22.3 mg, *p = 0.032), with transient antiemetic effects at 2 hours. The mean VAS scores at 2 and 4 post-operative hours were significantly different between both groups, respectively. The incidence of nausea and vomiting was significantly different at the second post-operative hour only.</p><p><strong>Conclusion: </strong>Metoclopramide significantly reduced early post-operative pain and opioid requirements, with reductions exceeding minimal clinically important difference thresholds. While statistically robust, these benefits should be weighed against its transient antiemetic effects and the need for larger trials to confirm functional recovery benefits.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"22 3","pages":"269-277"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular effects of novel synthetic opioids: A systematic review and narrative synthesis of current evidence.","authors":"Rajib Mandal, Sushrita Mahadani, Shubham Bhattacharya","doi":"10.5055/jom.0982","DOIUrl":"https://doi.org/10.5055/jom.0982","url":null,"abstract":"<p><strong>Introduction: </strong>The recent emergence of novel synthetic opioids (NSOs), including fentanyl analogs-eg, carfentanil, acetylfentanyl-and nonfentanyl drugs-eg, U-47700, nitazenes-on the drug market has caused high levels of morbidity and mortality. Even though their systemic toxicities have been well documented, their ocular effects have not been well explored. This review thus engages to systematically review the currently available clinical and experimental data on NSO-related ocular complications.</p><p><strong>Methods: </strong>According to Preferred Reporting Items for Systematic reviews and Meta-Analyses 2020 guidelines, the literature search was performed on PubMed, Scopus, Web of Science, ScienceDirect, and Google Scholar, which included all studies published up to May 2025. Our inclusion criterion entailed peer-reviewed articles on ocular outcomes following exposure of people to NSOs or in experimental animal models. Data extraction included study peculiarities, the type of opioids, ocular signs, and methodological quality. A narrative synthesis was performed due to heterogeneity in designs and outcomes.</p><p><strong>Results: </strong>After a thorough search of the literature, 759 records were retrieved, with five being included in the study: one observational case series, two narrative reviews, one animal study, and one literature review. The reported ocular symptoms included miosis, blurred vision, dry eye syndrome, and corneal dysfunction. Increased activity of the µ-opioid receptor was associated with pupillary constriction and ocular surface disease. In one study, topical naltrexone was highlighted as a promising tool that can reverse the effects of opioids on the cornea.</p><p><strong>Conclusion: </strong>Evidence suggests that NSOs, in particular, fentanyl analogs and U-47700, are related to a consortium of ocular manifestations. Such effects are especially significant in cases of overdose. Future studies should explore long-term visual outcomes and assessment of targeted interventions, including ocular µ-opioid receptor antagonists.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"22 3","pages":"299-308"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ketamine infusion as an adjunct therapy to aid opioid rotation to buprenorphine: A case series.","authors":"Thomas Chengxuan Lu, Laila Pravaresh, Apo Demirkol, Kok Eng Khor","doi":"10.5055/jom.0937","DOIUrl":"10.5055/jom.0937","url":null,"abstract":"<p><strong>Background: </strong>There are increasing rates of opioid prescriptions for chronic pain worldwide. Long-term opioid use for chronic noncancer pain is reported to be associated with problematic use and dependence. An effective way of improving patients' safety who are on high doses of potent opioids is utilizing buprenorphine rotation. Opioid rotation can be challenging due to the risk of precipitated withdrawals, which require mild-to-moderate opioid withdrawal symptoms. This can be highly stressful for patients and often leads to failure of the transition attempt. Ketamine is a short-acting N-methyl-D-aspartate antagonist analgesic with opioid-sparing properties. It can help mitigate opioid withdrawal symptoms and manage severe pain in individuals with opioid dependence.</p><p><strong>Case series: </strong>This case series presents four patients with noncancer chronic pain with comorbid opioid dependency, all of whom have failed outpatient attempts at opioid rotation to buprenorphine. These patients were admitted as inpatients, and ketamine infusion was utilized as an adjunct therapy in the facilitation of opioid rotation to buprenorphine/naloxone. All patients were successful in their opioid rotations. On follow-up, these patients had subjectively improved functioning without further aberrant behaviors pertaining to their opioids. All had either remained or reduced on the buprenorphine dose with follow-up.</p><p><strong>Conclusion: </strong>Ketamine infusion can be an effective adjunct therapy in facilitating opioid rotation for patients with chronic noncancer pain.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"22 3","pages":"329-337"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized trial evaluating pregabalin vs gabapentin on reducing opioid usage in patients with acute trauma injuries.","authors":"Nancy M Duvall, Wesley Kafka, Chisom L Maduakonam, Nancy Payne, Damayanti Samanta","doi":"10.5055/jom.0979","DOIUrl":"10.5055/jom.0979","url":null,"abstract":"<p><strong>Objective: </strong>Pregabalin and gabapentin have shown efficacy in reducing pain and opioid use, but limited data exist on their effectiveness in acute trauma patients. This study aimed to evaluate their impact on pain relief and opioid consumption in this population.</p><p><strong>Design: </strong>A prospective, unblinded, randomized trial.</p><p><strong>Setting: </strong>This study was conducted at a tertiary, academic Level I trauma center located in the southeastern region of the United States between 2021 and 2024.</p><p><strong>Patients: </strong>A total of 101 patients were included in the study and randomized into three groups: pregabalin, gabapentin, and a control group.</p><p><strong>Interventions: </strong>The pregabalin group received 50 mg of pregabalin, the gabapentin group received 300 mg of gabapentin, and the control group received neither. Drugs were administered every 8 or 12 hours, based on patients' creatinine -clearance.</p><p><strong>Main outcome measure: </strong>Patients' daily opioid intake during enrollment.</p><p><strong>Results: </strong>Total opioid and nonopioid analgesic use was similar across all groups. Median total opioid use was 69.5 morphine milligram equivalent (MME), 81.0 MME, and 66.3 MME, and nonopioid use was 5,362.5 mg, 6,600.0 mg, and 7,225.0 mg in the pregabalin, gabapentin, and neither groups, respectively. Likewise, average daily use of both opioid and nonopioid analgesics was comparable across groups. Median average daily pain scores ranged from 6.2 to 6.4, with no significant differences observed among the groups.</p><p><strong>Conclusions: </strong>Multimodal pain management in hospitalized trauma patients needs to be considered, especially in areas known for opioid misuse. Nonopioid analgesics aside from gabapentinoids may serve as an appropriate approach to manage pain in these individuals.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"22 3","pages":"241-249"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Midnight medicine: Empowering night shift to treat opioid use disorder (OUD).","authors":"Jessica Y Chambers, Kristin M Janzen, Alanna Boulton","doi":"10.5055/jom.0993","DOIUrl":"10.5055/jom.0993","url":null,"abstract":"<p><p>Hospitalizations for opioid use disorder (OUD) are rising, yet overnight clinicians rarely receive targeted OUD education. Our interprofessional initiative implemented two overnight training sessions specifically for night-shift physicians, nurses, pharmacists, and advanced practice providers, emphasizing buprenorphine initiation, stigma reduction, harm reduction, and patient-centered communication. Participants in the program demonstrated increased confidence in OUD management and a self-reported rise in overnight buprenorphine initiation, highlighting the impact of this tailored night-shift education. Administrative support enabled participation through scheduling adjustments and incentives, while collaboration with TeachOUD enriched content with community resources. To improve overnight care in resource-limited hospitals, we highlight no-cost resources, including teleconsultation hotlines, quick-reference tools, and training designated night-shift OUD champions, promoting accessible and sustainable strategies to enhance OUD care at all hours of the day.</p>","PeriodicalId":16601,"journal":{"name":"Journal of opioid management","volume":"22 2","pages":"129-133"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147973214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}